Among them, baricitinib was authorized for emergency use to treat hospitalized COVID-19 patients due to its capacity to block the JAK-STAT signaling pathway and the subsequent overproduction of cytokines in severe patients but also affecting viral endocytosis [79]. This evidence concerns the gene SOAT1 and COVID-19.